Comparative Pharmacology
Head-to-head clinical analysis: CU 7 versus HALOETTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CU 7 versus HALOETTE.
CU-7 vs HALOETTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The Cu-7 intrauterine device (IUD) releases copper ions, which inhibit sperm motility and viability, and alter the endometrial environment to prevent implantation.
Etonogestrel is a progestin that suppresses gonadotropin release, inhibiting ovulation and increasing cervical mucus viscosity.
50 mg orally once daily
One 13.9 mg subcutaneous etonogestrel implant inserted into the inner side of the non-dominant upper arm for contraception; effective for 3 years.
None Documented
None Documented
Not applicable; intrauterine device with no systemic elimination half-life. Copper release is continuous with a rate of approximately 38 µg/day, declining over time.
Terminal elimination half-life is approximately 1.3–1.7 hours (mean 1.5 hours). The short half-life supports continuous intravenous infusion for sustained sedation in critical care.
Primarily fecal (80-90%) as unabsorbed copper; negligible renal excretion (<1%).
Renal excretion of metabolites accounts for approximately 85–90% of elimination; biliary/fecal excretion accounts for 10–15%.
Category C
Category C
Contraceptive
Contraceptive